New tool could revolutionize cardiovascular risk management: PRESS score validated

The association between platelet hyperreactivity and the risk of cardiovascular events.

Cantourage Group SE welcomes draft bill of the Federal Ministry of Health on the new Cannabis Act and an amendment to the Medical Cannabis Act – Biotech Investments

EQS-News: Cantourage Group SE / Key word(s): Statement Cantourage Group SE welcomes draft bill of the Federal Ministry of Health on the new Cannabis Act

July 14, 2023

FLYSYN by VERAXA Biotech for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

FLYSYN is under clinical development by VERAXA Biotech and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).

February 9, 2024

Lung Function Stable in Sickle Cell Patients After Non-Myeloablative Transplant

Pulmonary function remained stable — and in some ways improved — among patients with sickle cell disease (SCD) who underwent non-myeloablative hematopoietic cell transplant (HCT),

August 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.